We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Illinois Retina Associates.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00690313
First Posted: June 4, 2008
Last Update Posted: June 4, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Alcon Research
Information provided by:
Illinois Retina Associates
May 30, 2008
June 4, 2008
June 4, 2008
July 2008
June 2009   (Final data collection date for primary outcome measure)
Timed study [ Time Frame: 1 year ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection

Antibiotic eye drops are being used before and after intravitreal injections. Currently there is no study indicating the benefit of there usage or their dosage.

In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior to the injection versus 1 day prior to intravitreal injection.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Intravitreal Injection Patients
Drug: Vigamox
eye drops 3 times day either 1 or 3 days prior to intravitreal injection
  • Active Comparator: Arm 1
    Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
    Intervention: Drug: Vigamox
  • Active Comparator: Arm 2
    Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
    Intervention: Drug: Vigamox
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
40
September 2009
June 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient who need intravitreal injections patients who are willing to participate in the study

Exclusion Criteria:

  • Patients who are allergic to Vigamox or who have taken any eye drops within the past 3 weeks
Sexes Eligible for Study: All
21 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00690313
Vig508
Not Provided
Not Provided
Not Provided
Kourous Rezaei MD, Illinois Retina Associates SC
Illinois Retina Associates
Alcon Research
Principal Investigator: Kourous A Rezaei, MD Illinois Retina Associates SC
Illinois Retina Associates
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP